patent-protected technology,0.719546
Phase II studies,-0.422466
vaccines,-0.278609
respiratory syncytial virus,-0.511922
product candidates,0.539361
Phase I/II studies,-0.560445
email newsletter,0.612878
clinical-stage biopharmaceutical company,0.25188
52-week low,-0.737096
beneficial proteins,0.719546
pivotal Phase II/III,-0.272017
infectious diseases,-0.69691
52-week high,-0.737096
hold rating,0.21098
email address,0.530175
related companies,0.612878
InvestorPlace Broker Center,0.555736
high fees,-0.735674
biopharmaceutical company,0.33509
research report,0.21098
foot-and-mouth disease,-0.744536
gene-based therapeutic drugs,0.418301
metastatic melanoma,-0.422466
advanced pancreatic cancer,-0.272017
Zacks Investment Research,0.40995
personal trading style,0.598412
neck cancer,-0.560445
Friday morning,0.21098
latest news,0.530175
GenVec Inc Daily,0.470406
buy rating,0.213811
simplex virus,-0.467088
HC Wainwright,0.216643
rectal cancer,-0.422466
research offerings,0.40995
proprietary adenovector technology,-0.708606
hearing loss,-0.659818
adenoviral-based product candidates,0.359175
balance disorders,-0.659818
concise daily summary,0.530175
Marketbeat.com reports,-0.206323
GenVec,-0.34695
stock broker,0.245696
pandemic flu,-0.70446
